The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 05, 2020

Filed:

Mar. 29, 2016
Applicant:

China Pharmaceutical University, Nanjing, CN;

Inventors:

Lianwen Qi, Nanjing, CN;

Lei Zhang, Nanjing, CN;

Tingting Wei, Nanjing, CN;

Yong Fan, Nanjing, CN;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/215 (2006.01); A61K 38/47 (2006.01); A61K 31/351 (2006.01); A61K 31/4375 (2006.01); A61K 31/7012 (2006.01); A61K 31/437 (2006.01); A61P 9/10 (2006.01);
U.S. Cl.
CPC ...
A61K 31/215 (2013.01); A61K 31/351 (2013.01); A61K 31/437 (2013.01); A61K 31/4375 (2013.01); A61K 31/7012 (2013.01); A61K 38/47 (2013.01); A61P 9/10 (2018.01);
Abstract

The present invention discloses an application of neuraminidase and inhibitors thereof in myocardial ischemia and myocardial infarction, provides a correlation between neuraminidase and myocardial ischemic damage to prove the myocardial ischemic damage can be alleviated by inhibiting the activity of neuraminidase, and to prove the neuraminidase can be used as a target for screening drugs for preventing, alleviating and/or treating myocardial ischemic damage. The present invention also demonstrates the alleviating effect of neuraminidase inhibitors on myocardial ischemic damage. Neuraminidase inhibitors improves myocardial ischemic damage by reducing the level of neuraminidase. The present invention further provides a pharmaceutical preparation comprising neuraminidase inhibitor(s) and pharmaceutically acceptable carrier(s), the pharmaceutical preparation can be used for reducing the level of neuraminidase, thus improving myocardial ischemic damage.


Find Patent Forward Citations

Loading…